title: Glycolysis back in the limelight: systemic targeting of HK2 blocks tumor growth.
abstract: In a recent issue of Cancer Cell, Patra and colleagues report findings that underscore the importance of Hexokinase 2 (HK2) in tumor initiation and maintenance. The authors also show that HK2 can be systemically deleted without adverse physiologic consequences. These findings provide attractive insights into HK2 deletion as a potential therapeutic intervention for cancer.
authors.affiliation: Gene Expression Analysis Laboratory, Cancer Research UK London Research Institute, London, United Kingdom.
authors.forename: Susana
authors.initials: S
authors.lastname: Ros
authors.forename: Almut
authors.initials: A
authors.lastname: Schulze
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival; D006019:Glycolysis; D006593:Hexokinase / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction
chemical_list: D006593:Hexokinase